Halozyme Therapeutics (HALO) – Research Analysts’ Weekly Ratings Changes

Halozyme Therapeutics (NASDAQ: HALO) has recently received a number of price target changes and ratings updates:

  • 11/16/2026 – Halozyme Therapeutics had its “buy” rating reaffirmed by TD Cowen.
  • 11/11/2026 – Halozyme Therapeutics was downgraded by Morgan Stanley from “overweight” to “equal weight”. They now have a $109.00 price target on the stock, up from $105.00.
  • 11/11/2026 – Halozyme Therapeutics was downgraded by Zacks Research from “strong-buy” to “hold”.
  • 11/9/2026 – Halozyme Therapeutics was upgraded by Weiss Ratings from “buy (b)” to “buy (b+)”.
  • 11/7/2026 – Halozyme Therapeutics was downgraded by Wall Street Zen from “strong-buy” to “buy”.
  • 11/6/2026 – Halozyme Therapeutics was downgraded by Leerink Partners from “outperform” to “hold”. They now have a $117.00 price target on the stock, up from $110.00.
  • 11/6/2026 – Halozyme Therapeutics had its price target raised by Citizens Jmp from $93.00 to $149.00. They now have a “market outperform” rating on the stock.
  • 11/6/2026 – Halozyme Therapeutics had its price target raised by Wells Fargo & Company from $95.00 to $110.00. They now have an “equal weight” rating on the stock.
  • 11/3/2026 – Halozyme Therapeutics had its price target raised by JPMorgan Chase & Co. from $78.00 to $79.00. They now have a “neutral” rating on the stock.
  • 10/16/2026 – Halozyme Therapeutics was given a new $130.00 price target by Stifel Nicolaus.
  • 10/13/2026 – Halozyme Therapeutics was upgraded by Zacks Research from “hold” to “strong-buy”.
  • 10/13/2026 – Halozyme Therapeutics had its price target raised by TD Cowen from $105.00 to $130.00. They now have a “buy” rating on the stock.
  • 10/8/2026 – Halozyme Therapeutics had its price target raised by JPMorgan Chase & Co. from $70.00 to $78.00. They now have a “neutral” rating on the stock.
  • 10/7/2026 – Halozyme Therapeutics had its price target raised by HC Wainwright from $115.00 to $130.00. They now have a “buy” rating on the stock.

Halozyme Therapeutics Stock Performance

NASDAQ HALO opened at $95.97 on Wednesday. The company’s 50 day simple moving average is $114.04 and its two-hundred day simple moving average is $85.75. The company has a debt-to-equity ratio of 13.50, a current ratio of 3.88 and a quick ratio of 3.60. Halozyme Therapeutics, Inc. has a 1 year low of $61.22 and a 1 year high of $134.00. The stock has a market capitalization of $10.94 billion, a PE ratio of 24.42, a P/E/G ratio of 0.36 and a beta of 0.92.

Halozyme Therapeutics (NASDAQ:HALO – Get Free Report) last released its quarterly earnings results on Thursday, November 5th. The biopharmaceutical company reported $2.39 EPS for the quarter, beating analysts’ consensus estimates of $2.30 by $0.09. The firm had revenue of $492.97 million during the quarter, compared to analyst estimates of $491.63 million. Halozyme Therapeutics had a net margin of 26.93% and a return on equity of 751.81%. The business’s revenue for the quarter was up 39.1% on a year-over-year basis. During the same period in the previous year, the business earned $1.72 EPS. Analysts predict that Halozyme Therapeutics, Inc. will post 8.34 earnings per share for the current fiscal year.

Insider Buying and Selling at Halozyme Therapeutics

In related news, CEO Helen Torley sold 20,000 shares of the business’s stock in a transaction dated Monday, November 16th. The stock was sold at an average price of $98.38, for a total transaction of $1,967,600.00. Following the completion of the transaction, the chief executive officer directly owned 767,780 shares in the company, valued at $75,534,196.40. The trade was a 2.54% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Matthew Posard sold 5,230 shares of the company’s stock in a transaction dated Thursday, October 1st. The stock was sold at an average price of $108.54, for a total value of $567,664.20. Following the completion of the transaction, the director owned 53,609 shares in the company, valued at $5,818,720.86. This represents a 8.89% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 144,226 shares of company stock valued at $15,262,493 in the last three months. 2.50% of the stock is owned by corporate insiders.

Halozyme Therapeutics, Inc. is a biotechnology company focused on developing drug-delivery technologies and medicines. Its ENHANZE platform uses a recombinant human hyaluronidase enzyme, rHuPH20, to temporarily modify tissue under the skin and help enable the subcutaneous administration of certain biologic medicines that might otherwise require intravenous infusion. Halozyme licenses ENHANZE to pharmaceutical and biotechnology partners, which use the technology in their own products. The company also markets Hylenex recombinant, a hyaluronidase product used to facilitate the dispersion and absorption of other injected medicines and fluids.

Read More

Receive News & Ratings for Halozyme Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halozyme Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.